This HTML5 document contains 110 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/wikipedia/
n27http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/pubchem-compound/
n22http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/kegg-drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00550/identifier/chebi/
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00550
rdf:type
n3:Drug
n3:description
A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
n3:dosage
n20:271B44C1-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 hours
n3:indication
Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
n3:manufacturer
n10:271B44B8-363D-11E5-9242-09173F13E4C5 n10:271B44BA-363D-11E5-9242-09173F13E4C5 n10:271B44BB-363D-11E5-9242-09173F13E4C5 n10:271B44B7-363D-11E5-9242-09173F13E4C5 n10:271B44B9-363D-11E5-9242-09173F13E4C5 n10:271B44BC-363D-11E5-9242-09173F13E4C5 n10:271B44BD-363D-11E5-9242-09173F13E4C5 n10:271B44B1-363D-11E5-9242-09173F13E4C5 n10:271B44B2-363D-11E5-9242-09173F13E4C5 n10:271B44B0-363D-11E5-9242-09173F13E4C5 n10:271B44B5-363D-11E5-9242-09173F13E4C5 n10:271B44B6-363D-11E5-9242-09173F13E4C5 n10:271B44B3-363D-11E5-9242-09173F13E4C5 n10:271B44B4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n22:DB00550 n28:DB00550
dcterms:title
Propylthiouracil
adms:identifier
n14:PA451156 n15:Propylthiouracil n16:657298 n17:D00562 n18:67253-651-10 n19:46505181 n23:8502 n24:C07569 n25:571424 n26:DB00550
n3:mechanismOfAction
Propylthiouracil binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. Therefore propylthiouracil effectively inhibits the production of new thyroid hormones.
n3:packager
n10:271B44AF-363D-11E5-9242-09173F13E4C5 n10:271B449F-363D-11E5-9242-09173F13E4C5 n10:271B44A6-363D-11E5-9242-09173F13E4C5 n10:271B44A7-363D-11E5-9242-09173F13E4C5 n10:271B44A4-363D-11E5-9242-09173F13E4C5 n10:271B44A5-363D-11E5-9242-09173F13E4C5 n10:271B44A2-363D-11E5-9242-09173F13E4C5 n10:271B44A3-363D-11E5-9242-09173F13E4C5 n10:271B44AE-363D-11E5-9242-09173F13E4C5 n10:271B44A0-363D-11E5-9242-09173F13E4C5 n10:271B44A1-363D-11E5-9242-09173F13E4C5 n10:271B44AC-363D-11E5-9242-09173F13E4C5 n10:271B44AD-363D-11E5-9242-09173F13E4C5 n10:271B44AA-363D-11E5-9242-09173F13E4C5 n10:271B44AB-363D-11E5-9242-09173F13E4C5 n10:271B44A8-363D-11E5-9242-09173F13E4C5 n10:271B44A9-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Propylthiouracil is readily absorbed and is extensively metabolized. Approximately 35% of the drug is excreted in the urine, in intact and conjugated forms, within 24 hours.
n3:synonym
Propylthiouracilum 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione Propylthiouracil Propylthiouracile 2-Mercapto-6-propyl-4-pyrimidone 6-Propylthiouracil 6-Propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one Propiltiouracilo 2-Thio-4-oxo-6-propyl-1,3-pyrimidine 2-Mercapto-6-propylpyrimid-4-one 2,3-dihydro-6-Propyl-2-thioxo-4(1H)-pyrimidinone 6-Thio-4-propyluracil 4-Propyl-2-thiouracil 2-Thio-6-propyl-1,3-pyrimidin-4-one
n3:toxicity
Oral, rat: LD<sub>50</sub> = 1250 mg/kg.
n11:hasAHFSCode
n27:68-36-08
n3:foodInteraction
Take at the same time everyday.
n3:proteinBinding
82%
n5:hasConcept
n6:M0017784
foaf:page
n8:propylthiouracil.html
n3:IUPAC-Name
n4:271B44C6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B44CC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B44CB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B44C8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B44C9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B44CA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B44DC-363D-11E5-9242-09173F13E4C5 n4:271B44C4-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B44DE-363D-11E5-9242-09173F13E4C5 n4:271B44C5-363D-11E5-9242-09173F13E4C5 n4:271B44C2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B44DF-363D-11E5-9242-09173F13E4C5 n4:271B44C3-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:H03BA02
n3:H-Bond-Acceptor-Count
n4:271B44D2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B44D3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B44CD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B44CE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B44D0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B44CF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B44D1-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51-52-5
n3:category
n3:containedIn
n9:271B44BF-363D-11E5-9242-09173F13E4C5 n9:271B44C0-363D-11E5-9242-09173F13E4C5 n9:271B44BE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B44D8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B44DA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B44DB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B44DD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B44D7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B44D6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B44D9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B44C7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B44D4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B44D5-363D-11E5-9242-09173F13E4C5